Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. This is a minor metadata change and does not affect study content or results.SummaryDifference0.1%

- Check39 days agoChange DetectedThe only change is a version update from v3.4.0 to v3.4.1; no study content, eligibility criteria, or results were affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded UI controls for Show glossary and Hide glossary, and updated the page revision label to Revision: v3.4.0. Minor capitalization changes to 'Last Update Submitted' and 'No FEAR Act' text were applied.SummaryDifference0.4%

- Check61 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed; this seems to be metadata/versioning information rather than a substantive change to content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded a dedicated 'Locations' section featuring the Colorado site. Removed the old 'Colorado Locations' entry and the 'HHS Vulnerability Disclosure' link from the footer.SummaryDifference0.2%

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.